LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate the efficacy and safety of ...

Actym Therapeutics has strengthened its IP portfolio with two newly issued patents covering its novel STACT™ biological ...

Global mRNA Cancer Vaccines Clinical Trials, Market Trends By Indication, Development Priority Status and Market Opportunity ...

At Fierce Healthcare, we keep track of all the venture capital being funneled into the health tech and digital health ...

In the CheckMate 274 study, adjuvant nivolumab demonstrated a significant improvement in disease-free survival (DFS) and showed a trend toward improved overall survival (OS) in an unselected ...

Twenty-eight students in the Jacobs School of Medicine and Biomedical Sciences were honored for outstanding achievements during the University at Buffalo’s 2025 Celebration of Student Academic ...

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next ...

The adaptive clinical trial design offers researchers the bold capability to make alterations in trial protocols by analyzing ...

Research suggests that AI chatbots can reduce anxiety during wartime, but human therapy delivers better results.

A blend of FSO and FSP models in the landscape of artificial intelligence can ensure CROs stay up to date with the unique ...

In the evolving field of neurodegenerative medicine, the challenge is not merely discovering new treatments but ensuri ...

32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer Enrollment into ... for Pharmaceuticals for Human Use consolidated Guideline for Good Clinical Practice, ...